Brussels, 11 March 2025

EuropaBio supports the recognition of biomanufacturing in the Critical Medicines Act as a solution to strengthen the EU’s autonomy and security of supply for Critical Medicines. We believe European institutions should also prioritise supporting novel technologies and access to raw materials and feedstocks, which are as critical as manufacturing capacity to secure resilience.

We believe the scope of the Act needs to be clarified to ensure it focuses on where vulnerabilities exist. EuropaBio regrets the lack of a proper impact assessment and calls on the Commission to rapidly deliver one to support the work of the co-legislators and mitigate potential impact on competition within the sector.

Dr. Claire Skentelbery, Director General, said “Strategic partnerships are critical to advance global biotech and biomanufacturing capacity and supply. The EU should increase support for biotech innovation, to secure its autonomy and resilience. That means working throughout the value chain, from access to raw materials and feedstocks to patients’ access.”

EuropaBio remains committed to engaging with stakeholders to support EU global competitiveness opportunities, making our industries stronger, greener and more innovative through biotech.